Enhanced local dendritic cell activity and tumor-specific immunoresponse in combined radiofrequency ablation and interleukin-2 for the treatment of human head and neck cancer in a murine orthotopic model

Head and Neck

Volumn 33, Issue 3, 2011, Pages 359-367

  Saito, Koichiro ^a   Araki, Koji ^a   Reddy, Nishant ^a   Guang, Wei ^a   O'Malley Jr , Bert W ^a   Li, Daqing ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

dendritic cell; gene therapy; head and neck cancer; interleukin 2; radiofrequency ablation

Indexed keywords

INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; HEAD AND NECK CARCINOMA; IMMUNE RESPONSE; LYMPH NODE; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; TREATMENT OUTCOME; TUMOR IMMUNITY; TUMOR VOLUME; VIRAL GENE THERAPY;

ANIMALS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CATHETER ABLATION; COMBINED MODALITY THERAPY; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; RANDOM ALLOCATION; RISK FACTORS; STATISTICS, NONPARAMETRIC; SURVIVAL RATE;

EID: 79951693943     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.21456     Document Type: Article

References (52)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ,. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66. (Pubitemid 46148091)
2. Beckmann GK, Hoppe F, Pfreundner L, Flentje MP,. Hyperfractionated accelerated radiotherapy in combination with weekly cisplatin for locally advanced head and neck cancer. Head Neck 2005; 27: 36-43. (Pubitemid 40024087)
3. Organ LW,. Electrophysiologic principles of radiofrequency lesion making. Appl Neurophysiol 1976-1977; 39: 69-76. (Pubitemid 8274031)
4. Owen RP, Ravikumar TS, Silver CE, Beitler J, Wadler S, Bello J,. Radiofrequency ablation of head and neck tumors: dramatic results from application of a new technology. Head Neck 2002; 24: 754-758. (Pubitemid 34857301)
5. Friedman M, Mikityansky I, Kam A, et al. Radiofrequency ablation of cancer. Cardiovasc Intervent Radiol 2004; 27: 427-434. (Pubitemid 39288080)
6. Kapural L, Mekhail N,. Radiofrequency ablation for chronic pain control. Curr Pain Headache Rep 2001; 5: 517-525.
7. Decadt B, Siriwardena AK,. Radiofrequency ablation of liver tumours: systematic review. Lancet Oncol 2004; 5: 550-560. (Pubitemid 39194044)
8. Hines-Peralta A, Goldberg SN,. Review of radiofrequency ablation for renal cell carcinoma. Clin Cancer Res 2004; 10 (18 Pt 2): 6328S-6334S. (Pubitemid 39287487)
9. Munver R, Del Pizzo JJ, Sosa RE,. Adrenal-preserving minimally invasive surgery: the role of laparoscopic partial adrenalectomy, cryosurgery, and radiofrequency ablation of the adrenal gland. Curr Urol Rep 2003; 4: 87-92.
10. Torriani M, Rosenthal DI,. Percutaneous radiofrequency treatment of osteoid osteoma. Pediatr Radiol 2002; 32: 615-618. (Pubitemid 36075761)
11. Lencioni R, Crocetti L, Cioni R, et al. Radiofrequency ablation of lung malignancies: where do we stand? Cardiovasc Intervent Radiol 2004; 27: 581-590. (Pubitemid 40064542)
12. Huston TL, Simmons RM,. Ablative therapies for the treatment of malignant diseases of the breast. Am J Surg 2005; 189: 694-701. (Pubitemid 40725740)
13. Owen RP, Silver CE, Ravikumar TS, Brook A, Bello J, Breining D,. Techniques for radiofrequency ablation of head and neck tumors. Arch Otolaryngol Head Neck Surg 2004; 130: 52-56. (Pubitemid 38095429)
14. Sánchez-Ortiz RF, Tannir N, Ahrar K, Wood CG,. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine? J Urol 2003; 170: 178-179. (Pubitemid 36734447)
15. Sinkovics JG, Horvath JC,. Vaccination against human cancers (review). Int J Oncol 2000; 16: 81-96.
16. Wissniowski TT, Hänsler J, Neureiter D, et al. Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res 2003; 63: 6496-6500. (Pubitemid 37255202)
17. den Brok MH, Sutmuller RP, van der Voort R, et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res 2004; 64: 4024-4029. (Pubitemid 38697319)
18. Alileche A,. Interleukin-2 and cancer: critical analysis of results, problems and expectations. Med Hypotheses 2003; 60: 202-208. (Pubitemid 36194292)
19. Berke G,. The CTL's kiss of death. Cell 1995; 81: 9-12.
20. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316: 889-897. (Pubitemid 17041979)
21. West WH, Tauer KW, Yannelli JR, et al. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 1987; 316: 898-905. (Pubitemid 17041980)
22. Donohue JH, Rosenberg SA,. The fate of interleukin-2 after in vivo administration. J Immunol 1983; 130: 2203-2208. (Pubitemid 13086760)
23. Cortesina G, De Stefani A, Galeazzi E, et al. The effect of preoperative local interleukin-2 (IL-2) injections in patients with head and neck squamous cell carcinoma. An immunological study. Acta Otolaryngol 1991; 111: 428-433.
24. Whiteside TL, Letessier E, Hirabayashi H, et al. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res 1993; 53: 5654-5662. (Pubitemid 23360267)
25. Cortesina G, De Stefani A, Galeazzi E, et al. Temporary regression of recurrent squamous cell carcinoma of the head and neck is achieved with a low but not with a high dose of recombinant interleukin 2 injected perilymphatically. Br J Cancer 1994; 69: 572-576. (Pubitemid 24076482)
26. De Stefani A, Valente G, Forni G, Lerda W, Ragona R, Cortesina G,. Treatment of oral cavity and oropharynx squamous cell carcinoma with perilymphatic interleukin-2: clinical and pathologic correlations. J Immunother Emphasis Tumor Immunol 1996; 19: 125-133. (Pubitemid 26139070)
27. O'Malley BW Jr, Sewell DA, Li D, et al. The role of interleukin-2 in combination adenovirus gene therapy for head and neck cancer. Mol Endocrinol 1997; 11: 667-673. (Pubitemid 27225294)
28. Li D, Jiang W, Bishop JS, Ralston R, O'Malley BW Jr,. Combination surgery and nonviral interleukin 2 gene therapy for head and neck cancer. Clin Cancer Res 1999; 5: 1551-1556. (Pubitemid 29282964)
29. Li D, Ronson B, Guo M, et al. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer. Cancer Res 2002; 62: 4023-4028. (Pubitemid 34791069)
30. Bray D, Yu SZ, Koprowski H II, et al. Combination nonviral interleukin 2 gene therapy and external-beam radiation therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg 2003; 129: 618-622. (Pubitemid 36682895)
31. Toujas L, Delcros JG, Diez E, et al. Human monocyte-derived macrophages and dendritic cells are comparably effective in vitro in presenting HLA class I-restricted exogenous peptides. Immunology 1997; 91: 635-642. (Pubitemid 27312349)
32. Klimp AH, de Vries EG, Scherphof GL, Daemen T,. A potential role of macrophage activation in the treatment of cancer. Crit Rev Oncol Hematol 2002; 44: 143-161. (Pubitemid 36159043)
33. Banchereau J, Steinman RM,. Dendritic cells and the control of immunity. Nature 1998; 392: 245-252. (Pubitemid 28155090)
34. de Vries IJ, Lesterhuis WJ, Scharenborg NM, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res 2003; 9: 5091-5100. (Pubitemid 37413557)
35. De Vries IJ, Krooshoop DJ, Scharenborg NM, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res 2003; 63: 12-17. (Pubitemid 36070411)
36. Savill J, Fadok V, Henson P, Haslett C,. Phagocyte recognition of cells undergoing apoptosis. Immunol Today 1993; 14: 131-136. (Pubitemid 23068298)
37. Williams MA, Newland AC, Kelsey SM,. The potential for monocyte-mediated immunotherapy during infection and malignancy. Part I: apoptosis induction and cytotoxic mechanisms. Leuk Lymphoma 1999; 34: 1-23. (Pubitemid 29248655)
38. Li D, Day KV, Yu S, et al. The role of adenovirus-mediated retinoblastoma 94 in the treatment of head and neck cancer. Cancer Res 2002; 62: 4637-4644.
39. O'Malley BW Jr, Cope KA, Johnson CS, Schwartz MR,. A new immunocompetent murine model for oral cancer. Arch Otolaryngol Head Neck Surg 1997; 123: 20-24. (Pubitemid 27043653)
40. Li D, Shugert E, Guo M, Bishop JS, O'Malley BW Jr,. Combination nonviral interleukin 2 and interleukin 12 gene therapy for head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2001; 127: 1319-1324. (Pubitemid 33041896)
41. Creak AL, Harrington K, Nutting C,. Treatment of recurrent head and neck cancer: re-irradiation or chemotherapy? Clin Oncol (R Coll Radiol) 2005; 17: 138-147. (Pubitemid 40468478)
42. Feldmann M, Londei M, Haworth C,. T cells and lymphokines. Br Med Bull 1989; 45: 361-370. (Pubitemid 19116525)
43. Mizuno H, Yanoma S, Nishimura G, et al. Therapeutic efficiency of IL-2 gene transduced tumor vaccine for head and neck carcinoma. Cancer Lett 2000; 152: 175-185. (Pubitemid 30201500)
44. Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N,. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000; 191: 423-434.
45. Cella M, Sallusto F, Lanzavecchia A,. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9: 10-16. (Pubitemid 27095893)
46. Inaba K, Pack M, Inaba M, Sakuta H, Isdell F, Steinman RM,. High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes. J Exp Med 1997; 186: 665-672. (Pubitemid 27381531)
47. Bender A, Bui LK, Feldman MA, Larsson M, Bhardwaj N,. Inactivated influenza virus, when presented on dendritic cells, elicits human CD8+ cytolytic T cell responses. J Exp Med 1995; 182: 1663-1671.
48. Bellone M, Iezzi G, Rovere P, et al. Processing of engulfed apoptotic bodies yields T cell epitopes. J Immunol 1997; 159: 5391-5399. (Pubitemid 127470066)
49. Albert ML, Sauter B, Bhardwaj N,. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392: 86-89. (Pubitemid 28150594)
50. Couch M, Saunders JK, O'Malley BW Jr, Pardoll D, Jaffee E,. Spatial distribution of tumor vaccine improves efficacy. Laryngoscope 2003; 113: 1401-1405. (Pubitemid 36944686)
51. Pardoll DM,. Spinning molecular immunology into successful immunotherapy. Nat Rev Immunol 2002; 2: 227-238. (Pubitemid 37323223)
52. Liu M, Acres B, Balloul JM, et al. Gene-based vaccines and immunotherapeutics. Proc Natl Acad Sci U S A 2004; 101 Suppl 2: 14567-14571.